| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000047304 |
| P356 | DOI | 10.1038/NRNEUROL.2009.219 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.219 |
| P932 | PMC publication ID | 2864089 |
| P698 | PubMed publication ID | 20140000 |
| P5875 | ResearchGate publication ID | 41414508 |
| P50 | author | Eliezer Masliah | Q28324209 |
| P2093 | author name string | Cynthia A Lemere | |
| P2860 | cites work | Cerebral hemorrhage after passive anti-Abeta immunotherapy. | Q48445999 |
| Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. | Q48463395 | ||
| Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. | Q48468481 | ||
| Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. | Q48486707 | ||
| Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. | Q48521871 | ||
| Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. | Q48553698 | ||
| Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. | Q48635943 | ||
| Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. | Q48713890 | ||
| Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. | Q48797820 | ||
| Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. | Q48863750 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. | Q48925662 | ||
| Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. | Q49011704 | ||
| Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 | ||
| Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. | Q51811574 | ||
| 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. | Q51893579 | ||
| Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
| A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads | Q53199877 | ||
| Cholinergic signaling in Alzheimer disease: therapeutic strategies. | Q53210288 | ||
| Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. | Q53238194 | ||
| Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. | Q53242663 | ||
| Shutting down Alzheimer's. | Q53378991 | ||
| Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD | Q58005269 | ||
| Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies | Q73827250 | ||
| Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals | Q74372174 | ||
| Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice | Q78758456 | ||
| APP binds DR6 to trigger axon pruning and neuron death via distinct caspases | Q22251088 | ||
| Forecasting the global burden of Alzheimer’s disease | Q22252403 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Biomarkers of Alzheimer's disease | Q24650667 | ||
| Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage | Q24791704 | ||
| Molecular basis for passive immunotherapy of Alzheimer's disease | Q27648521 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Alzheimer's disease: genes, proteins, and therapy | Q28131806 | ||
| Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
| Reversible memory loss in a mouse transgenic model of Alzheimer's disease | Q28591326 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. | Q30489052 | ||
| Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization | Q31128154 | ||
| A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease | Q33292093 | ||
| Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy | Q33332164 | ||
| Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers | Q33429289 | ||
| Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide | Q33630090 | ||
| Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders | Q33674688 | ||
| Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease | Q33943122 | ||
| Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. | Q34148927 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| The pathogenesis of senile plaques | Q34421483 | ||
| Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety | Q34687112 | ||
| Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid | Q34698382 | ||
| Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology | Q34763076 | ||
| Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets | Q34784378 | ||
| Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial | Q34798154 | ||
| Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. | Q44132564 | ||
| Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents | Q44474556 | ||
| Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome | Q45007178 | ||
| Dendrite and dendritic spine alterations in Alzheimer models | Q45099584 | ||
| Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide | Q45295828 | ||
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 | ||
| Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles | Q46332461 | ||
| Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. | Q46350343 | ||
| Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease | Q46496723 | ||
| A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. | Q46813624 | ||
| Synaptic and neuritic alterations during the progression of Alzheimer's disease | Q46842058 | ||
| Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease | Q46956885 | ||
| A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease | Q47583762 | ||
| Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. | Q47622833 | ||
| Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease | Q48007049 | ||
| Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. | Q48103179 | ||
| Imaging beta-amyloid burden in aging and dementia. | Q48168226 | ||
| Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice | Q48196624 | ||
| Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia | Q48210452 | ||
| Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity | Q48272962 | ||
| Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease | Q48300537 | ||
| Monoclonal antibodies that target pathological assemblies of Abeta | Q48363878 | ||
| Abeta species removal after abeta42 immunization | Q48378187 | ||
| Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions | Q35088160 | ||
| Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease | Q35169132 | ||
| Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis | Q35222076 | ||
| Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease | Q35477363 | ||
| Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice | Q35747037 | ||
| Intraneuronal Abeta42 accumulation in human brain. | Q35793325 | ||
| Deciphering the molecular basis of memory failure in Alzheimer's disease | Q35902501 | ||
| Immunological and anti-chaperone therapeutic approaches for Alzheimer disease | Q36075474 | ||
| Disaggregation of Alzheimer beta-amyloid by site-directed mAb. | Q36109944 | ||
| The molecular pathology of Alzheimer's disease | Q36490940 | ||
| Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice | Q36631376 | ||
| Re-evaluation of the structural organization of neuritic plaques in Alzheimer's disease. | Q36754613 | ||
| A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP. | Q36956833 | ||
| The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases | Q37064056 | ||
| DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype | Q37086973 | ||
| Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis | Q37103042 | ||
| Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease | Q37118356 | ||
| Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects | Q37181281 | ||
| Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization | Q37199687 | ||
| Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits | Q37301151 | ||
| Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease | Q37332710 | ||
| Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly | Q37391300 | ||
| Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy | Q37438261 | ||
| Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease | Q37456990 | ||
| Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice | Q39843065 | ||
| Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. | Q40139351 | ||
| Trajectories of brain loss in aging and the development of cognitive impairment | Q40149125 | ||
| Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease | Q40185375 | ||
| Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults | Q40253365 | ||
| Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide | Q40268982 | ||
| Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. | Q40328434 | ||
| Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. | Q40335208 | ||
| Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. | Q40453197 | ||
| HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. | Q40470395 | ||
| Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease | Q40666797 | ||
| Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias | Q40794805 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy | Q42087146 | ||
| Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease | Q42474769 | ||
| Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease | Q43142065 | ||
| Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease | Q43860008 | ||
| Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. | Q43913392 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 108-119 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Nature Reviews Neurology | Q2079285 |
| P1476 | title | Can Alzheimer disease be prevented by amyloid-beta immunotherapy? | |
| P478 | volume | 6 |
| Q28740910 | A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques |
| Q35040016 | A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory |
| Q37025979 | A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease |
| Q36240389 | A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease |
| Q37094019 | A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease |
| Q51029695 | A multimeric immunogen for the induction of immune memory to beta-amyloid. |
| Q34094661 | A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta |
| Q36964826 | A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice |
| Q33855619 | A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease. |
| Q99564822 | A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease |
| Q33771800 | A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease |
| Q27010785 | A window into the heterogeneity of human cerebrospinal fluid Aβ peptides |
| Q37435886 | Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease |
| Q26849352 | Advances in Alzheimer's disease drug development |
| Q37999086 | Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease. |
| Q28539753 | Aggregate-depleted brain fails to induce Aβ deposition in a mouse model of Alzheimer's disease |
| Q33831036 | Alum and squalene-oil-in-water emulsion enhance the titer and avidity of anti-Aβ antibodies induced by multimeric protein antigen (1-11)E2, preserving the Igg1-skewed isotype distribution |
| Q37057272 | Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules |
| Q27005935 | Alzheimer's disease, amyloid peptide and synaptic dysfunction |
| Q33349401 | Alzheimer's disease: clinical trials and drug development |
| Q37922808 | Alzheimer's disease: synapses gone cold |
| Q26829267 | Alzheimer's therapeutics: translation of preclinical science to clinical drug development |
| Q53318106 | Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease. |
| Q42286450 | Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy |
| Q38184618 | Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward |
| Q93014137 | Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses |
| Q30316057 | An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice |
| Q33639513 | Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis |
| Q33718694 | Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse |
| Q35058359 | Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease |
| Q37810562 | Antibody therapy in neurodegenerative disease |
| Q37117527 | Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission |
| Q34664345 | Antibody-derived in vivo imaging of tau pathology |
| Q38407177 | Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence |
| Q42247507 | Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade |
| Q38801554 | Asymmetric cerebral blood flow in patients with mild cognitive impairment: possible relationship to further cognitive deterioration |
| Q41465460 | Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice. |
| Q34344683 | BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases |
| Q37810956 | Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. |
| Q59811749 | Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in Aβ vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model |
| Q30651551 | Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease |
| Q38263669 | Biometals and their therapeutic implications in Alzheimer's disease. |
| Q42008541 | Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology |
| Q35095392 | Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice |
| Q27024202 | CD4 T cells in immunity and immunotherapy of Alzheimer's disease |
| Q50223200 | CNS inflammation and neurodegeneration. |
| Q38616051 | Cerebrospinal Fluid Amyloid-β 42, Total Tau, and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease |
| Q35827454 | Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration |
| Q34948575 | Co-immunization with DNA and protein mixture: a safe and efficacious immunotherapeutic strategy for Alzheimer's disease in PDAPP mice |
| Q38062334 | Combination of Aβ clearance and neurotrophic factors as a potential treatment for Alzheimer's disease |
| Q45300233 | Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease |
| Q37873869 | Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. |
| Q38240609 | Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease |
| Q40470312 | Conformational targeting of intracellular Aβ oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. |
| Q35875915 | Could immunomodulation be used to prevent prion diseases? |
| Q35964900 | Current perspectives on cardiac amyloidosis |
| Q35754215 | DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. |
| Q37701373 | Degeneration and repair in central nervous system disease |
| Q41909657 | Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses |
| Q42725476 | Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging |
| Q38095360 | Developing therapeutic antibodies for neurodegenerative disease |
| Q93178292 | Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay |
| Q35545974 | Drug development for Alzheimer's disease: recent progress |
| Q92605430 | Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice |
| Q30009187 | Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model |
| Q35185668 | Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model |
| Q34452239 | Enrichment and stratification for predementia Alzheimer disease clinical trials |
| Q37303082 | Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques |
| Q35807418 | Extracting β-amyloid from Alzheimer's disease |
| Q39594297 | Further evidence on mitochondrial targeting of β-amyloid and specificity of β-amyloid-induced mitotoxicity in neurons |
| Q38306065 | Further understanding of tau phosphorylation: implications for therapy. |
| Q38693732 | Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease |
| Q37727724 | Harnessing Nanoparticles for Immunomodulation and Vaccines |
| Q36246834 | How the interval between prime and boost injection affects the immune response in a computational model of the immune system. |
| Q34500145 | Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide |
| Q50574806 | Human umbilical cord blood-derived monocytes improve cognitive deficits and reduce amyloid-β pathology in PSAPP mice. |
| Q28660580 | IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA |
| Q50776088 | Identification and mapping of linear antigenic determinants of human amyloid ß(1-42) peptide. |
| Q83523354 | Identification of the shortest Aβ-peptide generating highly specific antibodies against the C-terminal end of amyloid-β42 |
| Q35772596 | IgG Conformer's Binding to Amyloidogenic Aggregates |
| Q36185908 | Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. |
| Q38187861 | Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines |
| Q36790089 | Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial |
| Q34565644 | Immunomodulation for prion and prion-related diseases |
| Q37634138 | Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. |
| Q38508754 | Immunotherapy Applied to Neuropsychiatric Disorders: a New Perspective of Treatment |
| Q38023156 | Immunotherapy for Alzheimer disease: the challenge of adverse effects. |
| Q37984574 | Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. |
| Q26823877 | Immunotherapy for Alzheimer's disease: hoops and hurdles |
| Q38222750 | Immunotherapy for Alzheimer's disease: past, present and future |
| Q38079317 | Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies |
| Q37899064 | Immunotherapy for tauopathies. |
| Q26781130 | Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation |
| Q26745928 | Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges |
| Q37639320 | Implications of Lifecourse Epidemiology for Research on Determinants of Adult Disease |
| Q64259170 | Ingredients in Zijuan Pu'er Tea Extract Alleviate β-Amyloid Peptide Toxicity in a Model of Alzheimer's Disease Likely through DAF-16 |
| Q37880893 | Intranasal delivery of therapeutic proteins for neurological diseases. |
| Q37179956 | Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial |
| Q38202185 | Investigational drugs in Alzheimer's disease: current progress |
| Q34566355 | Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples |
| Q35540628 | Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease |
| Q26772943 | Mechanism of Anti-α-Synuclein Immunotherapy |
| Q38773662 | Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model |
| Q35030015 | Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques |
| Q42038294 | Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease. |
| Q35579334 | Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease |
| Q53318372 | Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. |
| Q38808543 | Monophosphoryl Lipid-A: A Promising Tool for Alzheimer's Disease Toll |
| Q45733638 | Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology |
| Q37752915 | Murine models of Alzheimer's disease and their use in developing immunotherapies. |
| Q95936527 | Nanomedicine-based immunotherapy for central nervous system disorders |
| Q34096147 | Nasal mucosal inhalation of amyloid-beta peptide 3-10 defective adenovirus attenuates cytotoxicity induced by beta-amyloid (1-42). |
| Q38246262 | New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. |
| Q36221014 | OPTIMIZING DIAGNOSIS AND MANANGEMENT IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. |
| Q38131957 | On the subject of rigor in the study of amyloid β-protein assembly |
| Q38873518 | One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. |
| Q92608280 | Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4-10 Prevents Spatial Learning Decline |
| Q36597696 | Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission |
| Q37800059 | PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research |
| Q36904407 | Pathoetiology of multiple sclerosis: are we barking up the wrong tree? |
| Q26853610 | Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease |
| Q34630346 | Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum |
| Q57039635 | Peripheral immune system in aging and Alzheimer's disease |
| Q48858444 | Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice. |
| Q55512073 | Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. |
| Q26995405 | Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals |
| Q58804706 | Preclinical progression of neurodegenerative diseases |
| Q36391157 | Preventive immunization of aged and juvenile non-human primates to β-amyloid |
| Q53316653 | Production of anti-amyloid β antibodies in mice fed rice expressing amyloid β. |
| Q37473219 | Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine |
| Q34006399 | Protective effects of Acanthopanax divaricatus extract in mouse models of Alzheimer's disease |
| Q27005843 | Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease |
| Q38176899 | Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy |
| Q38844834 | RCAN1 overexpression promotes age-dependent mitochondrial dysregulation related to neurodegeneration in Alzheimer's disease |
| Q42778736 | Recent advances in the development of immunotherapies for tauopathies |
| Q53477029 | Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease. |
| Q34279689 | Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study |
| Q34043432 | Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model |
| Q41074700 | Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method |
| Q92075092 | Short-term fish oil supplementation applied in presymptomatic stage of Alzheimer's disease enhances microglial/macrophage barrier and prevents neuritic dystrophy in parietal cortex of 5xFAD mouse model |
| Q37728335 | Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease |
| Q37979840 | Solanezumab for the treatment of mild-to-moderate Alzheimer's disease |
| Q35216864 | Strong inhibition of beta-amyloid peptide aggregation realized by two-steps evolved peptides |
| Q46348872 | Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy |
| Q26822002 | Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics |
| Q90398264 | Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized With DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins |
| Q43074155 | Testing the amyloid hypothesis of Alzheimer's disease in vivo |
| Q36036555 | The Components of Flemingia macrophylla Attenuate Amyloid β-Protein Accumulation by Regulating Amyloid β-Protein Metabolic Pathway |
| Q33560798 | The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates |
| Q37575502 | The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review. |
| Q38501528 | The case for rejecting the amyloid cascade hypothesis. |
| Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
| Q35183183 | The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q37975816 | The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug |
| Q37827490 | Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? |
| Q37842339 | Therapeutic potential of vaccines for Alzheimer's disease |
| Q37311364 | Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology |
| Q36241902 | Ultrasound attacks Alzheimer's disease? |
| Q33613767 | Using NMR approaches to drive the search for new CNS therapeutics. |
| Q38188866 | Vaccination against Alzheimer disease: an update on future strategies |
| Q42513498 | Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice |
| Q35542169 | Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration |
Search more.